tiprankstipranks
Trending News
More News >
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196

Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

Compare
2 Followers

2196 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

3.47%94.70%
Insiders
3.47%
Mutual Funds
― Other Institutional Investors
94.70% Public Companies and
Individual Investors

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$11.52 and its highest was HK$19.50 in the past 12 months.
    What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
    Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is $67.22B.
      When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
      Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Sep 02, 2025 which is in 88 days.
        How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
        Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 30, 2025. The company reported HK$0.315 earnings per share for the quarter, missing the consensus estimate of HK$0.32 by -HK$0.005.
          Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
          According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
            Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 1.96%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
              What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
              Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.31.
                How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
                Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
                  What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
                  Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.315 in its last earnings report, missing expectations of HK$0.32. Following the earnings report the stock price went down -3.719%.
                    Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
                    Currently, no hedge funds are holding shares in HK:2196

                    Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

                    Company Description

                    Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

                    Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, is a leading healthcare conglomerate based in China. The company operates across various sectors, including pharmaceuticals, medical devices, healthcare services, and diagnostic products. Fosun Pharma is dedicated to the research, development, manufacturing, and marketing of pharmaceutical products and medical devices, aiming to improve health and well-being through innovation and quality.

                    2196 Stock 12 Month Forecast

                    Average Price Target

                    HK$14.20
                    ▼(-14.43%Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","16":"HK$16","19":"HK$19","22":"HK$22","25":"HK$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.2046557185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$14.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.2046557185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$14.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.2046557185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$14.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,16,19,22,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.12,14.126511978346153,14.133023956692307,14.139535935038461,14.146047913384615,14.15255989173077,14.159071870076923,14.165583848423076,14.17209582676923,14.178607805115384,14.185119783461538,14.191631761807692,14.198143740153846,{"y":14.2046557185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.12,14.126511978346153,14.133023956692307,14.139535935038461,14.146047913384615,14.15255989173077,14.159071870076923,14.165583848423076,14.17209582676923,14.178607805115384,14.185119783461538,14.191631761807692,14.198143740153846,{"y":14.2046557185,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.12,14.126511978346153,14.133023956692307,14.139535935038461,14.146047913384615,14.15255989173077,14.159071870076923,14.165583848423076,14.17209582676923,14.178607805115384,14.185119783461538,14.191631761807692,14.198143740153846,{"y":14.2046557185,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.365,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.89,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.225,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.409,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.31,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.836,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.542,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.972,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.128,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.037,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.979,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.979,"date":1696118400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.12,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Kingworld Medicines Group Ltd.
                    Sino Biopharmaceutical
                    China Resources Pharmaceutical Group Ltd.
                    Livzon Pharmaceutical Group
                    CSPC Pharmaceutical Group
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis